Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., announced on May 13, 2025, the signing of a binding term sheet with Modulant Biosciences. This agreement grants Modulant Biosciences exclusive global rights to develop and commercialize EL-22 for animal health applications.
This collaboration enables a first-of-its-kind probiotic approach to muscle preservation in livestock, leveraging EL-22's engineered probiotic technology. The agreement represents a strategic opportunity for Northstrive to monetize the intellectual property of EL-22 in the animal health sector.
If EL-22 is successfully developed and brought to market, this license could become a long-term revenue-generating asset for Northstrive Biosciences. This move diversifies the potential applications and commercial reach of its lead asset.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.